PhRMA

New free educational program launched – Explaining the U.S. Inflation Reduction Act
9 May 2023
We have launched a free online explainer to the U.S. Inflation Reduction Act. It makes essential viewing for anyone wanting a sound knowledge of the technical detail of the Act and how it relates to pharmaceutical payment and coverage.

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers
1 June 2022
In recent years, U.S. policymakers have been considering reforms to tackle high and rising prescription drug spending, including unprecedented direct limits on prices and price growth…

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies
1 March 2022
Generic preference-based measures are often used for capturing patients’ health-related quality of life (QOL) to assess quality-adjusted life years (QALYs) in health technology assessment (HTA). Whilst…
The Lower Drug Costs Now Act and Pharmaceutical Innovation
1 September 2021
The US spends significantly more on healthcare per person than other wealthy countries. H.R. 3 is a recent policy proposal aimed at reducing national spending on…

How is Quality of Life Measured for Health Technology Assessments?
1 July 2021
Cost-effectiveness analysis (CEA) is the economic evaluation method that is typically preferred by health technology assessment agencies. Quality-adjusted life years (QALYs) – a composite measure of quality and…

Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study
1 January 2017
PhRMA commissioned OHE Consulting to explore options and recommend methods that could help middle-income countries efficiently and effectively identify medicines for formulary inclusion. In a previous…

Policy Options for Formulary Development in Middle-income Countries
1 January 2017
PhRMA commissioned OHE Consulting to explore options and recommend methods that could help middle-income countries efficiently and effectively identify medicines for formulary inclusion. This report presents a framework…